InvivoGen Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • InvivoGen's estimated annual revenue is currently $22.3M per year.(i)
  • InvivoGen's estimated revenue per employee is $155,000

Employee Data

  • InvivoGen has 144 Employees.(i)
  • InvivoGen grew their employee count by 9% last year.

InvivoGen's People

NameTitleEmail/Phone
1
Chief Operating Officer, General Manager / Directeur GeneralReveal Email/Phone
2
Research Scientist/Lab ManagerReveal Email/Phone
3
Production ManagerReveal Email/Phone
4
R&D SupervisorReveal Email/Phone
5
Sales & Technical Support ManagerReveal Email/Phone
6
Directeur commercialReveal Email/Phone
7
PROJECT LEADERReveal Email/Phone
8
Science WriterReveal Email/Phone
9
Project LeaderReveal Email/Phone
10
WebmasterReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is InvivoGen?

At InvivoGen, we strive to provide life scientists worldwide with innovative, high quality and reliable reagents. As specialists in cell culture engineering and innate immunity, we are passionate about designing, developing, and bringing to market new tools and services for cutting-edge research. At our three regional headquarters — in Toulouse (France), San Diego (USA) and Hong Kong (China) — and through our dedicated multilingual customer support staff, we can provide researchers around the globe with the reagents and product information that they need to make the scientific breakthroughs of tomorrow. InvivoGen is a privately held company founded by university researchers in 1977 in Toulouse, France. Since then, we have gradually expanded with the opening of InvivoGen San Diego, in 1997, and InvivoGen Hong Kong, in 2014. Our unparalleled skills in microbial fermentation enable us to produce a wide range of bioactive molecules, including ultra-pure antibiotics, novel mycoplasma treatments and the largest available collection of pattern recognition receptor agonists, from various micro-organisms. Over 25% of InvivoGen’s employees hold a PhD in biology or chemistry. Through specialized R&D teams, they work together seamlessly to design, produce and validate novel plasmids, cell lines, vaccine adjuvants and synthetic ligands for research in areas as diverse as gene therapy, molecular immunology and vaccination. Moreover, based on our first-hand knowledge of innate immune receptor signaling pathways, we have devised an ever-expanding collection of reporter cell lines, including cytokine reporter cells and knockout (KO) cell lines for high-priority innate immune targets. Scientists depend on InvivoGen for quality, consistency and reliability. Whatever research challenges you are facing, count on InvivoGen to provide you with the tools and solutions that you need.

keywords:N/A

N/A

Total Funding

144

Number of Employees

$22.3M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$42.8M144-4%N/A
#2
$42.8M1447%N/A
#3
$46.3M145-6%N/A
#4
$29.1M145N/AN/A
#5
$32.7M1459%N/A